Preparation of nanoparticles for glioma and tuberculosis therapy
Project/Area Number |
22590040
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Physical pharmacy
|
Research Institution | Nagoya City University |
Principal Investigator |
OZEKI Tetsuya 名古屋市立大学, 大学院・薬学研究科, 教授 (60277259)
|
Co-Investigator(Kenkyū-buntansha) |
TATSUMI Taiga 名古屋市立大学, 大学院・薬学研究科, 講師 (10444043)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 粒子設計 / DDS |
Research Abstract |
As to nanoparticles design for treatment of glioma, seven-folates modified-β-cyclodextrin-anticancer drug were synthesized for specific targeting of drug to cancer cells. OCT3131, which is new candidate for anti-tuberculosis drug and highly water-soluble, was covered with hydrophobic surfactant to be nanoparticles. The nanoparticles can be existed as particles even in deeper site of lungs. Inhalable microparticles including OCT313 nanoparticles were prepared and it was successful to deliver drug in high efficient to alveolar macrophages which tuberculosis hides.
|
Report
(4 results)
Research Products
(38 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance, Chapter 11, Edited by Pere-Jaon Cardona2012
Author(s)
Takemasa Takii, Tasuhiro Horita, Ryuji Kuroishi, Taku Chiba, Mashami Mori, Tomohiro Hasegawa, Tatsuya Ito, Tatsuaki Tagami, Tetsuya Ozeki, Saotomo Ito, and Kikuso Onozaki
Publisher
INTECH
Related Report
-
-